Patient characteristic |
Female | 7 (33%) |
Male | 14 (67%) |
Age at diagnosis of BM, y | 67 (32-84) |
Melanoma-specific GPA score | 3 (1-4) |
Karnofsky performance status | 90 (80-90) |
Median no. of BM treated w/SRS | 1.5 (1-5) |
Median BM diameter (maximum axial), cm | 1.0 (0.2 - 2.4) |
No. with non-brain metastases | 19/21 |
No. with prior systemic therapy | 13/21 |
| Ipilimumab | 10/13 |
No. with BRAF directed therapy | 5/21 |
No. with elevated LDH | 3/12 |
Treatment characteristic |
No. with single fraction SRS | 11 (52%) |
| 21 Gy, # lesions | 19 |
| 20 Gy, # lesions | 1 |
| 18 Gy, # lesions | 3 |
No. with post-op RT (5 treatments) | 7 (33%) |
No. with whole brain RT | 3 (14%) |
Pembrolizumab dosage |
| 2 mg/kg | 18 (86%) |
| 10 mg/kg | 3 (14%) |
No. of pembro doses | 6.5 (1-38) |